Follow-up for women after treatment for cervical cancer: A systematic review

• Published in: Gynecologic oncology Vol. 114; no. 3; pp. 528 - 535
• Main Authors: Elit, Laurie, Fyles, Anthony W, Devries, Michaela C, Oliver, Thomas K, Fung-Kee-Fung, Michael
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2009
• Subjects: Cervical cancer; Female; Follow-up; Follow-Up Studies; Hematology, Oncology and Palliative Medicine; Humans; Obstetrics and Gynecology; Recurrence; Retrospective Studies; Surveillance tests; Systematic review; Uterine Cervical Neoplasms - therapy; Recurrence; Systematic review; Cervical cancer; Surveillance tests; Follow-up
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1016/j.ygyno.2009.06.001

Abstract Objective To determine the optimal recommended program for the follow-up of patients who are disease free after completed primary therapy for cervical cancer. Methods Systematic search of MEDLINE, EMBASE and the Cochrane Library databases (1980–November 2007). Results Seventeen retrospective trials were identified. Most studies reported similar intervals for follow-up and ranged from a low of 9 visits to a high of 28 visits over 5 years. Follow-up visits typically occurred once every 3–4 months for the first 2 years, every 6 months for the next 3 years and then annually until year 10. All 17 trials reported that a physical exam was performed at each visit. Vaginal vault cytology was analyzed in 13 trials. Other routine surveillance tests included chest x-ray, ultrasound, CT scans, MRI, intravenous pyelography and tumour markers. Median time to recurrence ranged from 7–36 months after primary treatment. Rates of recurrence ranged from 8–26% with 14–57% of patients recurring in the pelvis, and 15–61% of patients recurring at distant or multiple sites. Of the 8–26% of patients who experienced disease recurrence, the vast majority, 89–99%, had recurred by year 5. Upon recurrence, median survival was 7–17 months. Asymptomatic recurrent disease was detected using physical exam in 29–71%, chest x-ray in 20–47%, CT in 0–34% and vaginal vault cytology in 0–17% of patients, respectively. Conclusion There is modest low quality evidence to inform the most appropriate follow-up strategy for patients with cervical cancer who are clinically disease free after receiving primary treatment. Follow-up visits should include a complete physical examination whereas, frequent vaginal vault cytology does not add significantly to the detection of early disease recurrence. Patients should return to annual population-based screening after 5 years of recurrence-free follow-up.